Work

P48.21 Population Pharmacokinetics and Exposure-Response with Durvalumab Plus Platinum-Etoposide in ES-SCLC: Results from CASPIAN

Year: 2021

Type: conference-abstract

Source: Journal of Thoracic Oncology

DOI: 10.1016/j.jtho.2021.01.891

Authors: Y. Zheng, D. Jin, Y. Guan, M. Özgüroğlu, D. Trukhin, A. Poltoratskiy, Y. Chen, L. Havel, M. Hochmair, L. Paz-Ares, H. Jiang, J. Armstrong, C. Chen, Y.H. Liu, L. Roskos

Institutions: AstraZeneca (United States), Istanbul University-Cerrahpaşa, Istanbul University, Institute of Oncology NN Petrov, Charles University, Thomayer University Hospital, Universidad Complutense de Madrid, Hospital Universitario 12 De Octubre, AstraZeneca (United Kingdom)

Language: English

Topic: Lung Cancer Research Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W3136690647

Cites:

Cited by: 2

Related to: 10